INS and breast carcinoma: In line with emerging literature, our data support the role of SHBG as both a proxy marker of insulin sensitivity and exposure, hepatic function, as well as a potential diagnostic biomarker and therapeutic target in the management of PCOS, MASLD, and breast cancer (13, 14).